SCHEMBL1068518

SCHEMBL1068518

CCCCOC(=O)C(N)Cc1ccc(O)c(O)c1

nearest known ligand 0.57

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALOX15 P16050 4/20 0.57
KDM4E B2RXH2 3/20 0.57
RECQL P46063 3/20 0.57
HIF1A Q16665 3/20 0.57
HSD17B10 Q99714 3/20 0.57
USP2 O75604 2/20 0.57
ADORA3 P0DMS8 2/20 0.57
HTR2A P28223 2/20 0.57
PTGS2 P35354 2/20 0.57
TDP1 Q9NUW8 2/20 0.57
SLC7A5 Q01650 2/20 0.57
EGFR P00533 1/20 0.57
LCK P06239 1/20 0.57
FYN P06241 1/20 0.57
PTGS1 P23219 1/20 0.57
APP P05067 5/20 0.48
IAPP P10997 1/20 0.47
ESR1 P03372 4/20 0.45
ALOX12 P18054 3/20 0.45
MEN1 O00255 2/20 0.45

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL8257343 1.00 ALOX15 (0.57) ALOX15KDM4ERECQLHIF1AHSD17B10
Hydrochloric Acid SCHEMBL1148892 0.99 ALOX15 (0.56) ALOX15KDM4ERECQLHIF1AHSD17B10
SCHEMBL1070169 0.96 ALOX15 (0.56) ALOX15KDM4ERECQLHIF1AHSD17B10
SCHEMBL15275681 0.95 HSD17B10 (0.55) ALOX15KDM4ERECQLHIF1AHSD17B10
SCHEMBL11754702 0.95 HSD17B10 (0.55) ALOX15KDM4ERECQLHIF1AHSD17B10
SCHEMBL28115688 0.95 HSD17B10 (0.55) ALOX15KDM4ERECQLHIF1AHSD17B10
SCHEMBL6140024 0.92 ALOX15 (0.60) ALOX15KDM4ERECQLHIF1AHSD17B10
SCHEMBL15679070 0.92 ALOX15 (0.60) ALOX15KDM4ERECQLHIF1AHSD17B10
SCHEMBL16135503 0.90 ALOX15 (0.62) ALOX15KDM4ERECQLHIF1AHSD17B10
SCHEMBL22959852 0.90 ALOX15 (0.62) ALOX15KDM4ERECQLHIF1AHSD17B10

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 59 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11969401-B2 Compositions and methods for treating or limiting development of age-related macular degeneration ARIZONA BOARD OF REGENTS ON BEHALF OF THE UNIVERSITY OF ARIZONA (US) 2024-04-30 US disclosed
US-20220023245-A1 COMPOSITIONS AND METHODS FOR TREATING OR LIMITING DEVELOPMENT OF AGE-RELATED MACULAR DEGENERATION NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT 2022-01-27 US disclosed
EP-3917504-A1 COMPOSITIONS AND METHODS FOR TREATING OR LIMITING DEVELOPMENT OF AGE-RELATED MACULAR DEGENERATION Arizona Board of Regents on behalf of the University of Arizona (US) 2021-12-08 EP disclosed
CN-109956868-B Phenyl carboxylic acid derivatives, preparation method and application thereof 中国科学院上海药物研究所 2020-10-09 CN disclosed
WO-2020160256-A1 COMPOSITIONS AND METHODS FOR TREATING OR LIMITING DEVELOPMENT OF AGE-RELATED MACULAR DEGENERATION ARIZONA BOARD OF REGENTS ON BEHALF OF THE UNIVERSITY OF ARIZONA (US) 2020-08-06 WO disclosed
US-20180008671-A1 PROLONGED ANTI-DIABETIC EFFECT OF FIBROBLAST GROWTH FACTOR 1 (FGF1) UNIVERSITY OF WASHINGTON (US) 2018-01-11 US disclosed
US-9861600-B2 Methods and compositions for treating and identifying compounds to treat age-related macular degeneration treatment Arizona Board of Regents, A Body Corporate Of The State Of Arizona Acting For An On Behalf Of The University of Arizona (US) 2018-01-09 US disclosed
US-20170224637-A1 INTRANSAL DELIVERY OF CURCUMIN DePuy Synthes Products, Inc. (US) 2017-08-10 US disclosed
US-20160374960-A1 Method of Topically Administering a Curcumin Derivative JOHNSON & JOHNSON CONSUMER, INC. 2016-12-29 US disclosed
WO-2016130683-A1 PROLONGED ANTI-DIABETIC EFFECT OF FIBROBLAST GROWTH FACTOR 1 (FGF1) UNIVERSITY OF WASHINGTON (US) 2016-08-18 WO disclosed
US-20090326275-A1 USE OF NITROGEN-CONTAINING CURCUMIN ANALOGS FOR THE TREATMENT OF ALZHEIMERS DISEASE DEPUY SPINE, LLC 2009-12-31 US disclosed
WO-2009158407-A1 IONTOPHORETIC DELIVERY OF CURCUMIN AND CURCUMIN ANALOGS FOR THE TREATMENT OF ALZHEIMER'S DISEASE CODMAN & SHURTLEFF, INC. (US) 2009-12-30 WO disclosed
EP-2136797-A2 INTRANASALLY ADMINISTERING CURCUMIN IN A BOLUS OF HELIUM GAS TO TREAT ALZHEIMER'S DISEASE Codman & Shurtleff Inc. (US) 2009-12-30 EP disclosed
WO-2009129497-A2 METHODS AND COMPOSITIONS FOR TREATING AND IDENTIFYING COMPOUNDS TO TREAT AGE-RELATED MACULAR DEGENERATION ARIZONA BOARD OF REGENTS, A BODY CORP. OF THE STATE OF ARIZONA, ACTING FOR AND ON BEHALF OF THE UNIVERSITY OF ARIZONA (US) 2009-10-22 WO disclosed
WO-2009101616-A1 NOVEL CONJUGATES FOR TREATING NEURODEGENERATIVE DISEASES AND DISORDERS RAMOT AT TEL AVIV UNIVERSITY LTD. (IL) 2009-08-20 WO disclosed
US-20090087385-A1 Intranasally administering curcumin in a bolus of helium gas to treat alzheimers disease CODMAN & SHURTLEFF, INC. 2009-04-02 US disclosed
WO-2008131059-A2 INTRANASALLY ADMINISTERING CURCUMIN IN A BOLUS OF HELIUM GAS TO TREAT ALZHEIMER'S DISEASE CODMAN & SHURTLEFF, INC. (US) 2008-10-30 WO disclosed
US-20080076821-A1 INTRANASALLY ADMINISTERING CURCUMIN PRODRUGS TO THE BRAIN TO TREAT ALZHEIMER'S DISEASE DePuy Synthes Products, Inc. 2008-03-27 US disclosed
WO-1997016181-A1 METHOD FOR THE INTRANASAL ADMINISTRATION OF L-DOPA PRODRUGS UNIVERSITY OF KENTUCKY (US) 1997-05-09 WO disclosed
US-4021538-A Method for producing pigmentation in hair or skin YU RUEY J 1977-05-03 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20220023245-A1 COMPOSITIONS AND METHODS FOR TREATING OR LIMITING DEVELOPMENT OF AGE-RELATED MACULAR DEGENERATION MTNR1A, MC1R, MTNR1B ALOX15 674/4885KDM4E 3969/4885RECQL 3491/4885
US-20160374960-A1 Method of Topically Administering a Curcumin Derivative S100A11, S100A4, S100A6 ALOX15 48/4885KDM4E 1183/4885RECQL 4232/4885
US-20090326275-A1 USE OF NITROGEN-CONTAINING CURCUMIN ANALOGS FOR THE TREATMENT OF ALZHEIMERS DISEASE SLC1A3, SLC1A1, SLC1A2 ALOX15 350/4885KDM4E 3397/4885RECQL 4560/4885
US-11969401-B2 Compositions and methods for treating or limiting development of age-related macular degeneration MTNR1A, MC1R, MTNR1B ALOX15 674/4885KDM4E 3969/4885RECQL 3491/4885
US-20170224637-A1 INTRANSAL DELIVERY OF CURCUMIN FABP7, FABP2, NDUFB5 ALOX15 502/4885KDM4E 2958/4885RECQL 4218/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.